Login Register Cart 0
Generic placeholder image

Current HIV Research

Editor-in-Chief

ISSN (Print): 1570-162X
ISSN (Online): 1873-4251

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Real-Life Impact on Lipid Profile of a Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected Patients

Author(s): Jennifer Lagoutte-Renosi*, Mylène Flammang*, Catherine Chirouze, Geneviève Beck-Wirth, Fabienne Bozon, Anne-Sophie Brunel, Marie-Christine Drobacheff-Thiebaut, Adeline Foltzer, Laurent Hustache-Mathieu, Jakub Kowalczyk, Catherine Michel, Siamak Davani and Patrice Muret

Volume 19, Issue 1, 2021

Published on: 24 August, 2020

Page: [84 - 89] Pages: 6

DOI: 10.2174/1570162X18666200824101838

Price: $65

Abstract

Background: Tenofovir disoproxil fumarate is a prodrug of tenofovir diphosphate that exposes patients to renal toxicity over the long term. Tenofovir alafenamide, a new prodrug, now makes it possible to reduce toxicity, but at the cost of an alteration in lipid profile. There is currently no recommendation for follow-up of lipid profile when switching from tenofovir disoproxil fumarate to tenofovir alafenamide.

Objective: Our study aimed to evaluate the effects on renal function and lipid profile of a switch from tenofovir disoproxil fumarate to tenofovir alafenamide, and the consequences for patient management.

Methods: Demographic, clinical and biological data was recorded from a retrospective clinical cohort study in real-life, including patients who switched from tenofovir disoproxil fumarate to tenofovir alafenamide. A descriptive analysis of the study population, with a comparison of biological parameters using the paired Student t test for paired data was performed.

Results: From January 2016 to January 2019, a total of 103 patients were included. There was no significant difference in renal function before vs after the switch in therapy (p=0.29 for creatinine, p=0.30 for phosphoremia). We observed a change in lipid profile, with a significant increase in total cholesterol (p=0.0006), HDL cholesterol (p=0.0055) and triglycerides (p=0.0242). Four patients received lipid-lowering therapy after switching.

Conclusion: In patients who switch from tenofovir disoproxil fumarate to tenofovir alafenamide, lipid profile is altered, and may require initiation of lipid-lowering therapy. It seems necessary to monitor lipid parameters after this switch, despite the absence of an official recommendation.

Keywords: HIV, tenofovir alafenamide fumarate, tenofovir disoproxil fumarate, dyslipidemia, adverse events, hypolipidemic agents.

« Previous Next »
Graphical Abstract

[1]
Robbins BL, Srinivas RV, Kim C, Bischofberger N, Fridland A. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob Agents Chemother 1998; 42(3): 612-7.
[http://dx.doi.org/10.1128/AAC.42.3.612] [PMID: 9517941]
[2]
Casado JL. Renal and Bone Toxicity with the Use of Tenofovir: Understanding at the End. AIDS Rev 2016; 18(2): 59-68.
[PMID: 27230467]
[3]
del Palacio M, Romero S, Casado JL. The use of biomarkers for assessing HAART-associated renal toxicity in HIV-infected patients. Curr HIV Res 2012; 10(6): 521-31.
[http://dx.doi.org/10.2174/157016212802429802] [PMID: 22716111]
[4]
Ray AS, Fordyce MW, Hitchcock MJM. Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus. Antiviral Res 2016; 125: 63-70.
[http://dx.doi.org/10.1016/j.antiviral.2015.11.009] [PMID: 26640223]
[5]
Gotham D, Hill A, Pozniak AL. Candidates for inclusion in a universal antiretroviral regimen: tenofovir alafenamide. Curr Opin HIV AIDS 2017; 12(4): 324-33.
[http://dx.doi.org/10.1097/COH.0000000000000379] [PMID: 28403027]
[6]
GENVOYA® (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) tablets, for oral use. Available from:. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207561s013lbl.pdf [Accessed May 30, 2020].
[7]
ODEFSEY® (emtricitabine, rilpivirine, and tenofovir alafenamide) tablets, for oral use. Available from:. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208351Orig1s000Lbl.pdf [Accessed May 30, 2020].
[8]
BIKTARVY® (bictegravir, emtricitabine, and tenofovir alafenamide) tablets, for oral use. Available from:. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210251Orig1s000lbl.pdf [Accessed May 30, 2020].
[9]
Domingo P, Mateo MG, Gutierrez MDM, Vidal F. Tolerability of Current Antiretroviral Single-Tablet Regimens. AIDS Rev 2018; 20(3): 141-9.
[PMID: 30264826]
[10]
Tungsiripat M, Kitch D, Glesby MJ, et al. A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS 2010; 24(11): 1781-4.
[http://dx.doi.org/10.1097/QAD.0b013e32833ad8b4] [PMID: 20495438]
[11]
Crane HM, Grunfeld C, Willig JH, et al. Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care. AIDS 2011; 25(2): 185-95.
[http://dx.doi.org/10.1097/QAD.0b013e328341f925] [PMID: 21150555]
[12]
Santos JR, Saumoy M, Curran A, et al. Tenofovir/emtricitabine inflUence on LIPid metabolism (TULIP) Study Group. The lipid-lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial. Clin Infect Dis 2015; 61(3): 403-8.
[http://dx.doi.org/10.1093/cid/civ296] [PMID: 25870325]
[13]
Eron JJ, Orkin C, Gallant J, et al. A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients. AIDS 2018; 32(11): 1431-42.
[http://dx.doi.org/10.1097/QAD.0000000000001817] [PMID: 29683855]
[14]
Orkin C, Eron JJ, Rockstroh J, et al. Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients. AIDS 2020; 34(5): 707-18.
[http://dx.doi.org/10.1097/QAD.0000000000002463] [PMID: 31833849]
[15]
Clevenbergh P, Mouly S, Sellier P, et al. Improving HIV infection management using antiretroviral plasma drug levels monitoring: a clinician’s point of view. Curr HIV Res 2004; 2(4): 309-21.
[http://dx.doi.org/10.2174/1570162043351129] [PMID: 15544452]
[16]
Sax PE, Zolopa A, Brar I, et al. Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study. J Acquir Immune Defic Syndr 2014; 67(1): 52-8.
[http://dx.doi.org/10.1097/QAI.0000000000000225] [PMID: 24872136]
[17]
Sax PE, Wohl D, Yin MT, et al. GS-US-292-0104/0111 Study Team. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet Lond Engl 2015; 385: 2606-15.
[http://dx.doi.org/10.1016/S0140-6736(15)60616-X] [PMID: 25890673]
[18]
Orkin C, DeJesus E, Ramgopal M, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. Lancet HIV 2017; 4(5): e195-204.
[http://dx.doi.org/10.1016/S2352-3018(17)30031-0] [PMID: 28259777]
[19]
Gallant JE, Daar ES, Raffi F, et al. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial. Lancet HIV 2016; 3(4): e158-65.
[http://dx.doi.org/10.1016/S2352-3018(16)00024-2] [PMID: 27036991]
[20]
Mills A, Arribas JR, Andrade-Villanueva J, et al. GS-US-292-0109 team. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis 2016; 16(1): 43-52.
[http://dx.doi.org/10.1016/S1473-3099(15)00348-5] [PMID: 26538525]
[21]
Raffi F, Orkin C, Clarke A, et al. Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults. J Acquir Immune Defic Syndr 2017; 75(2): 226-31.
[http://dx.doi.org/10.1097/QAI.0000000000001344] [PMID: 28272164]
[22]
Milinkovic A, Berger F, Arenas-Pinto A, Mauss S. Reversible effect on lipids by switching from tenofovir disoproxil fumarate to tenofovir alafenamide and back. AIDS 2019; 33(15): 2387-91.
[http://dx.doi.org/10.1097/QAD.0000000000002350] [PMID: 31764103]
[23]
Cid-Silva P, Fernández-Bargiela N, Margusino-Framiñán L, et al. Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine. Basic Clin Pharmacol Toxicol 2018.
[PMID: 30388308]
[24]
Behrens G, Maserati R, Rieger A, et al. Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles. Antivir Ther (Lond) 2012; 17(6): 1011-20.
[http://dx.doi.org/10.3851/IMP2305] [PMID: 22910324]
[25]
Demacker PN, Schade RW, Jansen RT, Van ’t Laar A. Intra-individual variation of serum cholesterol, triglycerides and high density lipoprotein cholesterol in normal humans. Atherosclerosis 1982; 45(3): 259-66.
[http://dx.doi.org/10.1016/0021-9150(82)90227-1] [PMID: 7159498]

Rights & Permissions Print Cite
Article Metrics
19
© 2024 Bentham Science Publishers | Privacy Policy